CSEM has received questions from its members regarding the eligibility and safety of the COVID-19 vaccines and patients with endocrine conditions. Health Canada recommendations are changing rapidly. Recognizing there is little data to address groups excluded in the vaccine trials, a risk benefit assessment will need to be case-by-case and in consideration of national, provincial and local regulations.
CSEM supports equitable access to COVID-19 vaccines for individuals with endocrine conditions. Patients with type 1 diabetes, other autoimmune conditions, and immunocompromised health should have a risk/benefit discussion with their health care provider to make an informed decision. Some patients have multiple comorbidities that affect their vaccine status and patients may need to discuss with the relevant specialist(s).